Smith Moore & CO. bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, Holdings Channel reports. The fund bought 1,461 shares of the company’s stock, valued at approximately $242,000.

Other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in Becton, Dickinson and Company by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 16,848,347 shares of the company’s stock worth $3,028,153,000 after buying an additional 501,017 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Becton, Dickinson and Company by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,931,754 shares of the company’s stock worth $1,066,114,000 after buying an additional 82,813 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Becton, Dickinson and Company by 2.8% in the third quarter. BlackRock Fund Advisors now owns 4,469,437 shares of the company’s stock worth $803,292,000 after buying an additional 123,608 shares in the last quarter. Northern Trust Corp boosted its stake in Becton, Dickinson and Company by 2.5% in the third quarter. Northern Trust Corp now owns 2,657,873 shares of the company’s stock worth $477,701,000 after buying an additional 64,189 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Becton, Dickinson and Company by 13.9% in the second quarter. Bank of New York Mellon Corp now owns 2,395,262 shares of the company’s stock worth $406,211,000 after buying an additional 291,429 shares in the last quarter. 82.30% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 180.62 on Friday. The stock has a market capitalization of $38.44 billion, a PE ratio of 30.06 and a beta of 1.00. The company’s 50 day moving average price is $173.67 and its 200 day moving average price is $172.81. Becton, Dickinson and Company has a 52-week low of $142.38 and a 52-week high of $181.76.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, February 2nd. The company reported $2.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.12 by $0.21. The business earned $2.92 billion during the quarter, compared to analyst estimates of $2.86 billion. Becton, Dickinson and Company had a return on equity of 25.25% and a net margin of 10.54%. Becton, Dickinson and Company’s revenue was down 2.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.96 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post $9.43 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date of this dividend is Wednesday, March 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 48.42%.

This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this piece can be viewed at http://www.dailypolitical.com/2017/02/17/smith-moore-co-buys-new-stake-in-becton-dickinson-and-company-bdx.html.

BDX has been the topic of a number of recent research reports. Zacks Investment Research cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, November 16th. Raymond James Financial, Inc. reissued an “outperform” rating and issued a $180.00 target price (down from $200.00) on shares of Becton, Dickinson and Company in a research note on Thursday, January 5th. Leerink Swann reissued a “market perform” rating and issued a $185.00 target price (up from $180.00) on shares of Becton, Dickinson and Company in a research note on Monday, November 21st. RBC Capital Markets reissued a “hold” rating and issued a $177.00 target price on shares of Becton, Dickinson and Company in a research note on Friday, January 6th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $189.00 target price (down from $197.00) on shares of Becton, Dickinson and Company in a research note on Friday, November 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $176.39.

In other Becton, Dickinson and Company news, VP Jeffrey S. Sherman sold 31,464 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $180.02, for a total transaction of $5,664,149.28. Following the completion of the sale, the vice president now directly owns 22,094 shares of the company’s stock, valued at approximately $3,977,361.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Stephen Sichak sold 2,632 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 5th. The shares were sold at an average price of $164.44, for a total value of $432,806.08. Following the sale, the insider now directly owns 7,953 shares of the company’s stock, valued at $1,307,791.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,889 shares of company stock valued at $6,399,650. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

5 Day Chart for NYSE:BDX

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.